In a retrospective analysis of a randomized phase III trial among stage III HER2 negative breast cancer patients, this BRCA1-like classifier proved to be a strong predictive factor for better outcomes after treatment with high-dose alkylating chemotherapy with autologous stem cell transplantation compared to standard anthracycline-containing therapy (risk of recurrence in BRCA1-likeCGH HR 0.12 (0.04–0.43) vs. non-BRCA1-likeCGH HR 0.78 (0.50–1.20); p interaction 0.006) [49]. Here, ERBB2 is linked to breast carcinoma.